We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Assay for Thyroid-Stimulating Hormone

By HospiMedica staff writers
Posted on 16 Jun 2006
A new immunoassay for thyroid-stimulating hormone (TSH) is designed for the diagnosis of hyperthyroidism and hypothyroidism.

The ability to achieve third-generation sensitivity is essential for most TSH assays, since it yields information that is useful to clinicians referring patients with subnormal TSH concentrations, according to Olympus Life and Material Science Europa (Hamburg, Germany), which developed the assay. More...


The clinical benchmark for TSH is not its analytic sensitivity but its functional sensitivity. Functional sensitivity for TSH is normally defined as the lowest concentration at which the interassay coefficient of variation is ? 20%. This demonstrates the ability of the assay to discriminate euthyroid levels (0.4-4.0 µlU/ml) from the very low levels (< 0.01 µlU/ml) obtained in patients with thyrotoxicosis.

Olympus has announced that the latest performance verification of the assay on the new Olympus AU3000i immunoassay system delivered excellent functional sensitivity (fourth generation: ? 20% coefficient of variation (CV) @ 0.002 µlU/ml) and analytic sensitivity (< 0.001 µlU/ml). Based on this performance, the company concludes that the AU3000i TSH assay is a very sensitive and precise method for the detection of human TSH in both serum and plasma. These results would seem to justify the new assay as being regarded as fourth generation.



Related Links:
Olympus Life and Material Science

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.